B. Zinman, C. Wanner, and J. Lachin, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes, New England Journal of Medicine, vol.373, issue.22, pp.2117-2128, 2015.
DOI : 10.1056/NEJMoa1504720

D. Fitchett, B. Zinman, and C. Wanner, trial, European Heart Journal, vol.37, issue.19, pp.1526-1534, 2016.
DOI : 10.1093/eurheartj/ehv728

T. Lüscher and F. Paneni, Cardiovascular protection in the treatment of type 2 diabetes: a review of clinical trial results across drug classes, Am J Med, vol.130, issue.6, pp.18-29, 2017.

S. Inzucchi, B. Zinman, and C. Wanner, SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials, Diabetes and Vascular Disease Research, vol.369, issue.2, pp.90-100, 2015.
DOI : 10.2459/JCM.0000000000000039

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361459

I. Raz and A. Cahn, Heart failure: SGLT2 inhibitors and heart failure ??? clinical implications, Nature Reviews Cardiology, vol.13, issue.4, pp.185-186, 2016.
DOI : 10.1016/j.ahj.2010.05.032

C. Wanner, S. Inzucchi, and J. Lachin, Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes, New England Journal of Medicine, vol.375, issue.4, pp.323-334, 2016.
DOI : 10.1056/NEJMoa1515920

C. Wanner, . Empa-reg, and . Outcome, EMPA-REG OUTCOME: The Nephrologist's Point of View, The American Journal of Medicine, vol.130, issue.6, pp.63-72, 2017.
DOI : 10.1016/j.amjmed.2017.04.007

P. Fioretto, A. Zambon, M. Rossato, L. Busetto, and R. Vettor, SGLT2 Inhibitors and the Diabetic Kidney, Diabetes Care, vol.39, issue.Supplement 2, pp.165-171, 2016.
DOI : 10.2337/dcS15-3006

M. Skrti-c and D. Cherney, Sodium???glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy, Current Opinion in Nephrology and Hypertension, vol.24, issue.1, pp.96-103, 2015.
DOI : 10.1097/MNH.0000000000000084

M. Sarnak, A. Levey, and A. Schoolwerth, Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension, vol.42, pp.1050-1065, 2003.

C. Herzog, R. Asinger, and A. Berger, Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney International, vol.80, issue.6, pp.572-586, 2011.
DOI : 10.1038/ki.2011.223

K. Matsushita, M. Van-der-velde, and B. Astor, Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis, Lancet, vol.375, pp.2073-2081, 2010.

R. Foley, A. Murray, and S. Li, Chronic Kidney Disease and the Risk for Cardiovascular Disease, Renal Replacement, and Death in the United States Medicare Population, 1998 to 1999, Journal of the American Society of Nephrology, vol.16, issue.2, pp.489-495, 1998.
DOI : 10.1681/ASN.2004030203

Y. Wang, P. Katzmarzyk, R. Horswell, W. Zhao, J. Johnson et al., Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes, Kidney International, vol.85, issue.5, pp.1192-1199, 2014.
DOI : 10.1038/ki.2013.396

E. Schiffrin, M. Lipman, and J. Mann, Chronic Kidney Disease: Effects on the Cardiovascular System, Circulation, vol.116, issue.1, pp.85-97, 2007.
DOI : 10.1161/CIRCULATIONAHA.106.678342

J. Lutz, J. Menke, D. Sollinger, H. Schinzel, and K. Thurmel, Haemostasis in chronic kidney disease, Nephrology Dialysis Transplantation, vol.29, issue.1, pp.29-40, 2014.
DOI : 10.1093/ndt/gft209

A. Scheen, Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis, Diabetes & Metabolism, vol.42, issue.2, pp.71-76, 2016.
DOI : 10.1016/j.diabet.2015.12.005

M. Abdul-ghani, D. Prato, S. Chilton, R. Defronzo, and R. , SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study, Diabetes Care, vol.39, issue.5, pp.717-725, 2016.
DOI : 10.2337/dc16-0041

B. Scirica, D. Bhatt, and E. Braunwald, Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, New England Journal of Medicine, vol.369, issue.14, pp.1317-1326, 2013.
DOI : 10.1056/NEJMoa1307684

W. White, C. Cannon, and S. Heller, Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes, New England Journal of Medicine, vol.369, issue.14, pp.1327-1335, 2013.
DOI : 10.1056/NEJMoa1305889

J. Green, M. Bethel, and P. Armstrong, Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes, New England Journal of Medicine, vol.373, issue.3, pp.232-242, 2015.
DOI : 10.1056/NEJMoa1501352

R. Defronzo, The EMPA-REG study: What has it told us? A diabetologist???s perspective, Journal of Diabetes and its Complications, vol.30, issue.1, pp.1-2, 2016.
DOI : 10.1016/j.jdiacomp.2015.10.013

R. Hayward, P. Reaven, and W. Wiitala, Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes, New England Journal of Medicine, vol.372, issue.23, pp.2197-2206, 2015.
DOI : 10.1056/NEJMoa1414266

R. Holman, S. Paul, M. Bethel, D. Matthews, and H. Neil, 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes, New England Journal of Medicine, vol.359, issue.15, pp.1577-1589, 2008.
DOI : 10.1056/NEJMoa0806470

N. Sattar, Revisiting the links between glycaemia, diabetes and cardiovascular disease, Diabetologia, vol.55, issue.Suppl 2, pp.686-695, 2013.
DOI : 10.1007/s00125-012-2817-5

W. Cefalu, L. Leiter, and K. Yoon, Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial, The Lancet, vol.382, issue.9896, pp.941-950, 2013.
DOI : 10.1016/S0140-6736(13)60683-2

J. Bolinder, Ö. Ljunggren, and L. Johansson, Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin, Diabetes, Obesity and Metabolism, vol.28, issue.Suppl. 1, pp.159-169, 2014.
DOI : 10.1111/dom.12189

M. Ridderstråle, K. Andersen, C. Zeller, G. Kim, H. Woerle et al., Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial, The Lancet Diabetes & Endocrinology, vol.2, issue.9, pp.691-700, 2014.
DOI : 10.1016/S2213-8587(14)70120-2

C. Fox, M. Pencina, P. Wilson, N. Paynter, R. Vasan et al., Lifetime Risk of Cardiovascular Disease Among Individuals With and Without Diabetes Stratified by Obesity Status in the Framingham Heart Study, Diabetes Care, vol.31, issue.8, pp.1582-1584, 2008.
DOI : 10.2337/dc08-0025

A. Ptaszynska, E. Hardy, E. Johnsson, S. Parikh, and J. List, Effects of Dapagliflozin on Cardiovascular Risk Factors, Postgraduate Medicine, vol.35, issue.6, pp.181-189, 2013.
DOI : 10.1056/NEJMoa1208500

G. Schernthaner, J. Gross, and J. Rosenstock, Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea, Diabetes Care, vol.36, issue.9, pp.2508-2515, 2013.
DOI : 10.2337/dc12-2491

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747923

J. Wilding, G. Charpentier, and P. Hollander, Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial, International Journal of Clinical Practice, vol.13, issue.Suppl. G, pp.1267-1282, 2013.
DOI : 10.1111/ijcp.12322

M. Odden, A. Amadu, E. Smit, L. Lo, and C. Peralta, Uric Acid Levels, Kidney Function, and Cardiovascular Mortality in US Adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002, American Journal of Kidney Diseases, vol.64, issue.4, pp.550-557, 2014.
DOI : 10.1053/j.ajkd.2014.04.024

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177300

B. Haas, N. Eckstein, V. Pfeifer, P. Mayer, and M. Hass, Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin, Nutrition & Diabetes, vol.37, issue.11, p.143, 2014.
DOI : 10.2337/dc12-2491

C. Campos, Chronic Hyperglycemia and Glucose Toxicity: Pathology and Clinical Sequelae, Postgraduate Medicine, vol.358, issue.24, pp.90-97, 2012.
DOI : 10.1210/jc.2008-2534

F. Giacco and M. Brownlee, Oxidative Stress and Diabetic Complications, Circulation Research, vol.107, issue.9, pp.1058-1070, 2010.
DOI : 10.1161/CIRCRESAHA.110.223545

S. Dassanayaka and S. Jones, O-GlcNAc and the cardiovascular system, Pharmacology & Therapeutics, vol.142, issue.1, pp.62-71, 2014.
DOI : 10.1016/j.pharmthera.2013.11.005

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943723

U. Karunakaran and N. Jeoung, O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease, Korean Diabetes Journal, vol.34, issue.4, pp.211-219, 2010.
DOI : 10.4093/kdj.2010.34.4.211

URL : http://doi.org/10.4093/kdj.2010.34.4.211

D. Montaigne, X. Marechal, and A. Coisne, Myocardial Contractile Dysfunction Is Associated With Impaired Mitochondrial Function and Dynamics in Type 2 Diabetic but Not in Obese Patients, Circulation, vol.130, issue.7, pp.554-564, 2014.
DOI : 10.1161/CIRCULATIONAHA.113.008476

A. Jobori, H. , D. G. Martinez, and R. , Empagliflozin improves beta-cell function measured with the hyperglycemic clamp in T2DM, Diabetes, vol.65, p.286, 2016.

M. Kern, N. Kloting, M. Mark, E. Mayoux, T. Klein et al., The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin, Metabolism, vol.65, issue.2, pp.114-123, 2016.
DOI : 10.1016/j.metabol.2015.10.010

E. Ferrannini, E. Muscelli, and S. Frascerra, Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients, Journal of Clinical Investigation, vol.124, issue.2, pp.499-508, 2014.
DOI : 10.1172/JCI72227

G. Daniele, J. Xiong, and C. Solis-herrera, Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes, Diabetes Care, vol.39, issue.11, pp.2036-2041, 2016.
DOI : 10.2337/dc15-2688

R. Defronzo, Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009, Diabetologia, vol.150, issue.Suppl 2, pp.1270-1287, 2009.
DOI : 10.1007/s00125-010-1684-1

W. Kernan, C. Viscoli, and K. Furie, Pioglitazone after Ischemic Stroke or Transient Ischemic Attack, New England Journal of Medicine, vol.374, issue.14, pp.1321-1331, 2016.
DOI : 10.1056/NEJMoa1506930

J. Buse, R. Defronzo, and J. Rosenstock, The primary glucoselowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies, Diabetes Care, vol.39, pp.198-205, 2016.

E. Messaoudi, S. Rongen, G. Riksen, and N. , Metformin Therapy in Diabetes: The Role of Cardioprotection, Current Atherosclerosis Reports, vol.26, issue.Suppl 2, p.314, 2013.
DOI : 10.1007/s11883-013-0314-z

P. Elliott, B. Andersson, and E. Arbustini, Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases, European Heart Journal, vol.29, issue.2, pp.270-276, 2008.
DOI : 10.1093/eurheartj/ehm342

P. Seferovic and W. Paulus, Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes, European Heart Journal, vol.36, issue.27, pp.1718-1727, 2015.
DOI : 10.1093/eurheartj/ehv134

M. Lehrke and N. Marx, Diabetes Mellitus and Heart Failure, The American Journal of Medicine, vol.130, issue.6, pp.40-50, 2017.
DOI : 10.1016/j.amjmed.2017.04.010

G. Aubert, O. Martin, and J. Horton, The Failing Heart Relies on Ketone Bodies as a Fuel, Circulation, vol.133, pp.698-705, 2016.
DOI : 10.1161/CIRCULATIONAHA.115.017355

N. Fillmore, J. Mori, and G. Lopaschuk, Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy, British Journal of Pharmacology, vol.101, issue.8, pp.2080-2090, 2014.
DOI : 10.1111/bph.12475

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976623

S. Mudaliar, S. Alloju, and R. Henry, Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis, Diabetes Care, vol.39, issue.7, pp.1115-1122, 2016.
DOI : 10.2337/dc16-0542

K. Bedi, . Jr, N. Snyder, and J. Brandimarto, Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure, Circulation, vol.133, pp.706-716, 2016.
DOI : 10.1161/CIRCULATIONAHA.115.017545

N. Jorgensen, J. Pedersen, and A. Vaag, EMPA-REG: Glucose excretion and lipid mobilization ??? not storage ??? saves lives, Journal of Diabetes and its Complications, vol.30, issue.4, p.753, 2016.
DOI : 10.1016/j.jdiacomp.2016.02.015

E. Ferrannini, M. Mark, and E. Mayoux, CV Protection in the EMPA-REG OUTCOME Trial: A ???Thrifty Substrate??? Hypothesis, Diabetes Care, vol.39, issue.7, pp.1108-1114, 2016.
DOI : 10.2337/dc16-0330

H. Taegtmeyer, Failing Heart and Starving Brain, Circulation, vol.134, issue.4, pp.265-266, 2016.
DOI : 10.1161/CIRCULATIONAHA.116.022141

G. Lopaschuk and S. Verma, Empagliflozin???s Fuel Hypothesis: Not so Soon, Cell Metabolism, vol.24, issue.2, pp.200-202, 2016.
DOI : 10.1016/j.cmet.2016.07.018

J. Newman and E. Verdin, ??-hydroxybutyrate: Much more than a metabolite, Diabetes Research and Clinical Practice, vol.106, issue.2, pp.173-181, 2014.
DOI : 10.1016/j.diabres.2014.08.009

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414487

J. Newman and E. Verdin, Ketone bodies as signaling metabolites, Trends in Endocrinology & Metabolism, vol.25, issue.1, pp.42-52, 2014.
DOI : 10.1016/j.tem.2013.09.002

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176946

M. Maalouf, P. Sullivan, L. Davis, D. Kim, and J. Rho, Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation, Neuroscience, vol.145, issue.1, pp.256-264, 2007.
DOI : 10.1016/j.neuroscience.2006.11.065

M. Haces, K. Hernandez-fonseca, O. Medina-campos, T. Montiel, J. Pedraza-chaverri et al., Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions, Experimental Neurology, vol.211, issue.1, pp.85-96, 2008.
DOI : 10.1016/j.expneurol.2007.12.029

J. Mcmurray and . Empa-reg-the, EMPA-REG ??? the ???diuretic hypothesis???, Journal of Diabetes and its Complications, vol.30, issue.1, pp.3-4, 2016.
DOI : 10.1016/j.jdiacomp.2015.10.012

D. Cherney, B. Perkins, and N. Soleymanlou, The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus, Cardiovascular Diabetology, vol.13, issue.1, p.28, 2014.
DOI : 10.1186/1475-2840-13-28

N. Marx and D. Mcguire, Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus, European Heart Journal, vol.37, issue.42, pp.3192-3200, 2016.
DOI : 10.1093/eurheartj/ehw110

L. Nainggolan, How is empagliflozin working in type 2 diabetes in EMPA-REG? Available at: http://www.medscape.com/viewarticle/ 865481, 2016.

P. Sarafidis and A. Tsapas, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, vol.374, p.1092, 2016.

B. Zinman, J. Lachin, and S. Inzucchi, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. (Correspondence), N Engl J Med, vol.374, p.1094, 2016.
DOI : 10.1056/nejmoa1504720

W. Cushman, G. Evans, and R. Byington, Effects of intensive blood-pressure control in type 2 diabetes mellitus, N Engl J Med, vol.362, pp.1575-1585, 2010.

X. Xie, E. Atkins, and J. Lv, Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis, The Lancet, vol.387, issue.10017, pp.435-443, 2016.
DOI : 10.1016/S0140-6736(15)00805-3

A. Scheen, Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics, Diabetes & Metabolism, vol.42, issue.4, pp.224-233, 2016.
DOI : 10.1016/j.diabet.2016.05.006

C. Emdin, K. Rahimi, B. Neal, T. Callender, V. Perkovic et al., Blood Pressure Lowering in Type 2 Diabetes, JAMA, vol.313, issue.6, pp.603-615, 2015.
DOI : 10.1001/jama.2014.18574

D. Cherney, B. Perkins, and N. Soleymanlou, Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus, Circulation, vol.129, issue.5, pp.587-597, 2014.
DOI : 10.1161/CIRCULATIONAHA.113.005081

H. Rajasekeran, Y. Lytvyn, and D. Cherney, Sodium???glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis, Kidney International, vol.89, issue.3, pp.524-526, 2016.
DOI : 10.1016/j.kint.2015.12.038

M. Fischereder and U. Schonermarck, Empagliflozin, cardiovascular outcomes , and mortality in type 2 diabetes, N Engl J Med, vol.374, pp.1092-1093, 2016.

N. Sattar, J. Mclaren, S. Kristensen, D. Preiss, and J. Mcmurray, SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?, Diabetologia, vol.166, issue.7, pp.1333-1339, 2016.
DOI : 10.1007/s00125-016-3956-x

URL : http://doi.org/10.1007/s00125-016-3956-x

A. Ceriello, S. Genovese, E. Mannucci, and E. Gronda, Glucagon and heart in type 2 diabetes: new perspectives, Cardiovascular Diabetology, vol.4, issue.374, p.123, 2016.
DOI : 10.1161/CIR.0000000000000426

URL : http://doi.org/10.1186/s12933-016-0440-3

B. Jones, T. Tan, and S. Bloom, Minireview: Glucagon in Stress and Energy Homeostasis, Endocrinology, vol.153, issue.3, pp.1049-1054, 2012.
DOI : 10.1210/en.2011-1979

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281544

C. Bonner, J. Kerr-conte, and V. Gmyr, Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion, Nature Medicine, vol.2, issue.5, pp.512-517, 2015.
DOI : 10.1038/nm.3828

D. Cherney, B. Perkins, and N. Soleymanlou, Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes, Kidney International, vol.86, issue.5, pp.1057-1058, 2014.
DOI : 10.1038/ki.2014.246

L. Heerspink, H. De-zeeuw, D. Wie, L. Leslie, B. List et al., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes, Diabetes, Obesity and Metabolism, vol.375, issue.9, pp.853-862, 2013.
DOI : 10.1111/dom.12127

I. Tikkanen, R. Chilton, and O. Johansen, Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension, Current Opinion in Nephrology and Hypertension, vol.25, issue.2, pp.81-86, 2016.
DOI : 10.1097/MNH.0000000000000199

M. Muskiet, D. Van-raalte, E. Van-bommel, M. Smits, L. Tonneijck et al., Understanding EMPA-REG OUTCOME, The Lancet Diabetes & Endocrinology, vol.3, issue.12, pp.928-929, 2015.
DOI : 10.1016/S2213-8587(15)00424-6

F. Jiang, Y. J. Zhang, and Y. , Angiotensin-converting enzyme 2 and angiotensin 1???7: novel therapeutic targets, Nature Reviews Cardiology, vol.279, issue.7, pp.413-426, 2014.
DOI : 10.1038/nrcardio.2014.59

S. Mudaliar, D. Polidori, B. Zambrowicz, and R. Henry, Sodium???Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport, Diabetes Care, vol.38, issue.12, pp.2344-2353, 2015.
DOI : 10.2337/dc15-0642

M. Sano, M. Takei, Y. Shiraishi, and Y. Suzuki, Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys, Journal of Clinical Medicine Research, vol.8, issue.12, pp.844-847, 2016.
DOI : 10.14740/jocmr2760w

E. Lip-sic, B. Westenbrink, and P. Van-der-meer, Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit, European Journal of Heart Failure, vol.28, issue.1, pp.22-29, 2008.
DOI : 10.1016/j.ejheart.2007.10.008

R. Grempler, L. Thomas, and M. Eckhardt, Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors, Diabetes, Obesity and Metabolism, vol.53, issue.1, pp.83-90, 2012.
DOI : 10.1111/j.1463-1326.2011.01517.x

M. Pfeffer, B. Claggett, and R. Diaz, Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome, New England Journal of Medicine, vol.373, issue.23, pp.2247-2257, 2015.
DOI : 10.1056/NEJMoa1509225

URL : http://www.zora.uzh.ch/119538/1/Lixisenatide%20in%20pts.pdf

S. Marso, G. Daniels, and K. Brown-frandsen, Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes, New England Journal of Medicine, vol.375, issue.4, pp.311-322, 2016.
DOI : 10.1056/NEJMoa1603827